Trump accelerates psychedelic drug research

In a significant shift in federal drug policy, the Trump administration is fast-tracking research into previously taboo substances for medical use.

The new executive order specifically targets ibogaine, a plant-based psychedelic that proponents claim can cure severe depression and addiction.

During the signing ceremony in the Oval Office, Trump was joined by Joe Rogan and Health Secretary Robert F. Kennedy Jr., both of whom have advocated for alternative mental health treatments.

While the policy provides $50 million for clinical studies, medical professionals remain cautious due to the drug's current classification as a high-risk illegal substance.